정신분열병에 대한 리스페리돈의 효과 및 안정성

이민수,김용구,김영훈,연병길,오병훈,윤도준,윤진상,이철,정희연,강병조,김광수,김동언,김명정,김상훈,김희철,나철,노승호,민경준,박기창,박두병,백기청,백인호,손봉기,손진욱,양병환,양창국,우행원,이정호,이종범,이홍식,임기영,전태연,정영조,정영철,정인과,정인원,지익성,채정호,한상익,한선호,한진희,서광윤 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.1

연구목적 : 본 시험의 목적은 임상시험 시작전에 연구자들을 대상으로 PANSS Workshop을 통하여 PANSS, ESRS에 대한 국내에서의 표준화 작업을 구축하고 새로운 정신병 치료제인 리스페리돈의 효과와 안정성을 재확인하여 리스페리돈 사용에 대한 적정화를 이루는데 있다. 연구방법 : 1996년 4월부터 1996년 9월까지 국내 39개 대학병원 정신과에 입원중인 혹은 증상이 악화되어 입원하는 정신분열병 환자 377명을 대상으로 다시설 개방 연구를 시행하였다. 1주일간의 약물 배설기간을 가진후, 리스페리돈을 8주간 투여하였고, 기준점, 1주, 2주, 4주, 그리고 8주후에 평가되었다. 용량은 제1일에는 리스페리돈 1mg씩 1일 2회, 제2일에는 2mg씩 1일 2회, 제3∼7일에는 3mg씩 1일 2회 투여하였다. 이후 환자의 임상상태에 따라 임의로 증량할 수 있으며, 최대 일일 16mg을 초과하지 않도록 하였다. 추체외로 증상을 조절하기 위한 투약을 허용하였다. 임상증상 및 부작용의 평가는 PANSS(Positive and Negative Syndrome Scale), CGI(Clinical Global Impression) 그리고 ESRS(Extrapyramidal Symptom Rating Scale)을 사용하였다. 연구결과 : 377명중 343명(91%)이 8주간의 연구를 완결하였다. 치료 종결시점인 8주후 PANSS 총점수가 20% 이상 호전된 경우를 약물 반응군으로 정의할때, 약물반응군은 81.3%였다. 리스페리돈에 반응하는 예측인자로는 발병연령, 이전의 입원 횟수, 유병기간이 관련 있었다. 리스페리돈은 1주후부터 PANSS양성, 음성, 및 일반정신병리 점수상에 유의한 호전을 보여 효과가 빨랐다. CGI의 경우도 기준점에 비해 1주후부터 유의한 감소를 나타내었다. ESRS의 경우, 파킨슨 평가점수는 기준점과 비교해 투여 1주, 2주, 4주후 유의하게 증가되었다가 8주후 기준점과 차이가 없었다. Dystonia 평가점수는 1주후만 유의한 증가를 보였으며, dyskinesia 평가점수는 유의한 차이가 없었다. 혈압, 맥박수의 생명징후 및 일반 혈액학 검사, 생화학적 검사, 심전도 검사에서 유의한 변화는 없었다. 결 론 : 이상의 다시설 개방 임상 연구를 통해 리스페리돈은 정신분열병 환자에서 양성증상뿐만 아니라 음성증상 및 전반적인 증상에도 효과적인 것으로 사료된다. 보다 명확한 평가를 위해서는 다른 항정신병약물과의 이중맹검 연구가 필요할 것으로 생각되며, 또한 장기적 치료에 대한 평가도 함께 이루어져야 하겠다. Objective : The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method : This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points ; at baseline, and 1, 2, 4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results : 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action ; a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. Conclusions : This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.

흥미로운 구조를 가진 Dipyrrolylbenzene들의 합성에 관한 연구

정대일,김인식,정두희,박철우,김윤영 東亞大學校 大學院 1996 大學院論文集 Vol.21 No.-

1-(2-Aminophenyl)pyrrole 20a and 1,2-dipyrrolylbenzene 17a were synthesized by using 1,2-phenylenediamine 16a with 2,5-dimethoxytetrahydrofuran 12 in glacial acid. 1-(3-Aminophenyl)pyrrole 20b and 1,3-dipyrrolylbenzene 17b were obtained by using 1,3-phenylenediamine 16b with 2,5-dimethoxytetrahydrofuran 12 in glacial acetic acid. 1,4-Dipyrrolybenzene 17c was synthesized by using 1,4-phenylenediamine 16c with 2,5-dimethoxytetrahydrofuran 12 in glacial acetic acid. Aminophenylpyrroles 20 and dipyrrolylbenzenes 17 were respectively synthesized by the treatment of 1,2-phenylenediamine 16a, 13-phenylenediamine 16b, 1,4-phenylenediamine 16c and 2,5-dimethoxytetrahydrofuran 12 in no solvent, acrylic acid, silica-gel, acrylic acid + silica-gel + acetic acid instead of glacial acetic acid. In case of silica-gel + acetic acid among various methods reactivity about synthesis of dipyrrolylbenzene 17 was best. 9-Phenylcarbazole 15 was synthesized by treatment of 1-phenylpyrrole 13 with 2,5-dimethoxytetrahydrofuran 12 in glacial acetic acid.

Nortropinone 유도체로부터 Nortropane Spirohydantoin 유도체의 합성

정대일,박유미,박종훈,김윤영,정두희,김인식 東亞大學校 1998 東亞論叢 Vol.35 No.-

The nortropinones 11 (tropinone lla, N-isopropylnortropinone 11b, N-Carbethoxynortropinone 11c, N-furfurylnortropinone 11d, N-(p-methoxyphenyl)nortropinone 11e) were respectively synthesized by the treatment of acetonedicarboxylic acid 8 with, 2, 5-dimethoxytetrahydrofurane 9 in various amines 10 (methylamine 10a, N-isopropylamine 10b, ethylcarbamate 10c, furfurylamine 10d, p-anisidine 10e). The nortropane spirohydantoins 14 (tropane spirohydanttoin 14a, N-isopropylnortropane spirohydantoin 14b, N-Carbethoxynortropane spirohydantoin 14c, N-furfurylnortropane spirohydantion 14d, n_(p-methoxyphenyl) nortropane spirohydantoin 14e) were respectively synthesized by the treatment of synthesized nortropinones 11 (tropinone 11a 54%, N-isopropylnortropinone 11b 50%, N-Carbethoxynortropinone 11c 58%, N-furfurylnortropinone 11d 31%, N-(p-methoxyphenyl) nortropinone 11e, 70%) with potassium cyanide 12, ammonium carbonate 13.

集賢殿 學士 硏究

鄭杜熙 전북대사학회 1980 전북사학 Vol.4 No.-

소아의 척추 외상

두정희,양홍기 한국전문물리치료학회 1996 한국전문물리치료학회지 Vol.3 No.1

Thioamide와 Benzothiazole 유도체의 합성

정대일,신규하,김인식,김윤영,정두희,이용균 東亞大學校 1998 東亞論叢 Vol.35 No.-

The thioamides; {N-(6-methyl-2-pyridinecarbothionyl)-3-methoxyaminobenzene (27), N-(6-methyl-2-pyridinecarbothionyl)-4-methoxyaminobenzene (29), N-(6-methyl-2-pyridine-carbothionyl)-3-ethoxyaminobenzene (31), N-(6-methyl-2-pyridinecarbothionyl)-4-ethoxyamion-benzene (33), N-(6-methyl-2-pyridinecarbothionyl)-3-bromoaminobenzene (35), N-(6-methyl-2-pyridinecarbothionyl)4-bromoaminobenzene (37), N-(6-methyl-2-pyridinecarbothionyl)-3-chloroaminobenzene (39), N-(6-methyl-2-pyridinecarbothionyl)-4-chloroaminobenzene (41)} were synthesized by the treatment of 2,6-lutidine(22) with sulfur in aniline derivatives (23). The benzothiazole derivatives; {5-methoxy-2-(6-methylpyridy)benzothiazole (46) and 6-ethoxy-2-(6-methylpyridyl)benzothiazole (47)} were respecively synthesized by the treatment of synthesized thioamides; N-(6-methyl-2-pyridinecarbothionyl)-3-methoxy-aminobenzene (27) and N-(6-methyl-2-pyridinecarbothionyl)-4-ethoxyaminobenzene (33) with zirconium (Ⅳ) oxide catalyst in sodium carbonate solution.

정상아동 4,5세를 대상으로 한 상자와 나무토막검사의 검사-재검사의 신뢰도검사 : Test-Retest Reliability for 4,5 Years Old Children

정민예,이재신,두정희 한국전문물리치료학회 1996 한국전문물리치료학회지 Vol.3 No.3

Acylthiocholine의 합성

정두희,이지현,박유미,정대일,곽문정,신영주 東亞大學校附設基礎科學硏究所 1998 基礎科學硏究論文集 Vol.15 No.2

Choline esters that are used with substrate of EE-AChE-catalyzed hydrolyses were synthesized by two methods. 2-Chloroethyl thiohexanoate 4a, 2-chloroethyl thioheptanoate 4c, and 2-chloroethyl thiooctanoate 4b were synthesized by treatment of hexanoyl chloride 3a, heptanoyl chloride 3c, and octanoyl chloride 3b with ethylene sulfide 2. Hexanoylthiocholine 6a and octanoylthiocholine 6b were synthesized by using 4a and 4b with trimethylamine 5. Secondly after reaction ethylene sulfide 2 with dimethyl amine 7 and acylation by acid anhydride 8, heptanoylthiocholine 6c, decanoylthiocholine 6d were synthesized by treatment of methyl iodide.

북제주군지역의 토지이용형태와 용천수의 수질특성

이용두,송희경,안중기 제주대학교 해양과환경연구소 2005 해양과환경연구소 연구논문집 Vol.29 No.1

간세포 배양기술을 이용한 생인공간 개발 현황

이두훈,윤희훈,박정극 한국화학공학회 2004 Korean Chemical Engineering Research(HWAHAK KONGHA Vol.42 No.2

우리 인체의 장기 중 간(liver)은 생존에 그 어느 장기보다도 중요한 역할을 담당하는 장기로서 여러 가지 원인으로 인하여 갑자기 간의 기능이 상실된 환자에게는 간이식만이 유일한 대안이다. 간세포를 이용한 체외 순환형 간 보조 장치(생인공간, bioartificial liver)는 최근 유일하게 전격성 간부적 환자의 생존을 중대 효과가 검증되었고 간이식이나 환자 자신의 간 재생으로의 생명 연장 교량 역할을 효과적으로 수행할 수 있을 것으로 기대되고 있다. 본 논문에서는 생인공간의 개념과 임상시험 중인 대표적인 생인공간 시스템 현황에 대해서 공학적 관점 위주로 소개하고 향후 이 분야에 대한 연구전망에 대하여 서술하였다. The liver is mutifunctional vital organ for healthy survival and orthotopic liver transplantation is the only definitive therapy for patients with acute or fulminant hepatic failure(FHF) so far. Bioartificial liver, a hepatocyte-based extracorporeal liver support system, enhanced the survival rates of patients with FHF and expected to act as a bridge to provide the extension of survival time until a donor organ becomes available for transplantation or their own liver can be regenerated. In this paper, we introduce concepts of bioartificial liver and review representative bioartifical liver systems in clinical trials with engineering issue. Finally we describe future perspectives of bioartificial liver.